Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [electronic resource]
Producer: 20091015Description: 543-55 p. digitalISSN:- 1083-4087
- Adjuvants, Immunologic -- administration & dosage
- Adolescent
- Adult
- Cost-Benefit Analysis
- Disease Progression
- Glatiramer Acetate
- Humans
- Injections, Intramuscular
- Injections, Subcutaneous
- Interferon beta-1a
- Interferon beta-1b
- Interferon-beta -- administration & dosage
- Middle Aged
- Models, Economic
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Peptides -- economics
- Randomized Controlled Trials as Topic
- Young Adult
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.